BioNTech将测试疫苗是否对变种新冠病毒有效 调整疫苗只需六星期
英国变种新型冠状病毒株正在蔓延,BioNTech(BNYX.US)表示,将需要两周的时间来测试与辉瑞(PFE.US)共同开发的疫苗是否仍能发挥有效作用,不过公司亦可使用现有技术在6周内生产出针对变种病毒株的疫苗。
BioNTech行政总裁Ugur Sahin表示,认为目前的疫苗仍然有效,由於疫苗使用mRNA技术,日後可以根据变种病毒株直接设计疫苗,并且在6周内生产。
BioNTech表示,目前目标是在今年底之前包括向欧盟提供1,250万剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.